Westfield Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Westfield Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-684,694	Closed	-$73.5M	–	254
2023 Q1	$73.5M	Buy	684,694 +366,520	+115%	+$42.2M	0.52%	66
2022 Q4	$35M	Buy	+318,174	New	+$20.6M	0.27%	126

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Westfield Capital Management's RXDX Position: Q2 2023 in Review

Westfield Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 684,694 shares — an estimated $73.5M sold.

Westfield Capital Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $73.5M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Westfield Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Westfield Capital Management sold 684,694 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $73.5M.
Westfield Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Westfield Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $73.5M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Westfield Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.